Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MN Prior Auth Drug List | O…
    Ask Trek AI about this page
    Currentblue cross blue shield - minnesotaPolicy N/A

    Provider-Administered Precertification Drug List

    Customize your policy alerts

    Sign up for all blue cross blue shield - minnesota policy alerts

    Know when blue cross blue shield - minnesota releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    List of provider-administered drugs that require precertification when given in office, outpatient facility, or home health settings; gene therapy/cellular immunotherapy products on the list require precertification regardless of place of treatment.

    Policy Summary
    Payerblue cross blue shield - minnesota
    PolicyProvider-Administered Precertification Drug List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior authorization) for listed provider-administered drugs when administered in a provider's office, outpatient facility, or home health setting; products marked + require precertification in any place of treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    300+drugs listed for precertification
    +gene therapy marker
    *

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Avastin note

    Precertification Coverage Criteria

    Precertification requirement

    Covered when administrative precertification requirements are met for listed drugs:

    Precertification for listed provider-administered drugs: Precertification obtained when drug is administered in a provider's office, outpatient facility, or home health setting

    Products marked with + require precertification in any place of treatment

    Special product categories: Treatments indicated as Gene Therapy/Cellular Immunotherapy (marked with +) require precertification regardless of place of treatment
    Avastin exception: For Avastin, prior authorization is required for oncology indications only

    For Avastin, prior authorization is required for oncology indications only. This policy requires precertification for drugs on the provider‑administered list when administered in a provider’s office, outpatient facility, or home health setting; gene therapy/cellular immunotherapy products (marked with a +) require precertification regardless of place of treatment.

    Provider Requirements and Actions

    Prior Authorization

    Prior Authorization Required

    Precertification (prior authorization) is required for the drugs on the Provider‑Administered Precertification Drug List when administered in a provider's office, outpatient facility, or home health setting. Treatments marked with a plus (+) are Gene Therapy/Cellular Immunotherapy products and require precertification when administered in any place of treatment.

    • Precertification required for all listed provider-administered drugs when administered in a provider office, outpatient facility, or home health setting.
    • Products marked with + (Gene Therapy/Cellular Immunotherapy) require precertification for administration in any place of treatment.
    • For Avastin (*), precertification is required for oncology indications only.
    Documentation Required

    Documentation Requirement

    Precertification documentation must be submitted for listed provider-administered drugs as part of the prior authorization request. Include clinical rationale, indication, treatment setting, dose and schedule, and copies of relevant medical records. For products marked with +, include documentation specific to gene therapy/cellular immunotherapy administration and any required companion diagnostic or registry information.

    Applicable Sites of Care

    Billing Rule

    Site‑of‑care precertification requirement

    Precertification is required when the listed drugs are administered in a provider's office, outpatient facility, or home health setting; gene therapy/cellular immunotherapy products (marked +) require precertification in any place of treatment.

    • Covered settings: office, infusion center/outpatient facility, home health (hospital outpatient is included on the list header)
    • Products marked + are subject to PA regardless of treatment location

    Key Definitions

    Gene Therapy/Cellular Immunotherapy (+)
    DefinitionProducts indicated as Gene Therapy/Cellular Immunotherapy are marked with a + and require precertification when administered in any place of treatment.
    Marker meaning+ indicates Gene Therapy/Cellular Immunotherapy product.
    Precertification scopeThese +‑marked products require precertification regardless of where treatment is given (office, outpatient facility, home, or hospital outpatient).
    List update cadenceThis provider‑administered drug list is updated monthly and is subject to change without notice.
    Source guidanceOnline provider‑administered drug policies are available via the payer's online policy portal ('Provider‑Administered Drug Policies').

    Policy Background

    This document is an administrative list identifying which provider‑administered drugs require prior precertification under the payer’s Provider‑Administered Drug Review Program. The list is updated monthly and subject to change. Products indicated as Gene Therapy/Cellular Immunotherapy are marked with a + and require precertification in any place of treatment. Failure to obtain required precertification when drugs are administered in a provider’s office, outpatient facility, or home health setting may result in denial of coverage.

    Policy Summary
    Payerblue cross blue shield - minnesota
    PolicyProvider-Administered Precertification Drug List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior authorization) for listed provider-administered drugs when administered in a provider's office, outpatient facility, or home health setting; products marked + require precertification in any place of treatment.
    SourceLink
    On This Page
    Precertification Coverage CriteriaProvider Requirements and ActionsApplicable Sites of CareKey DefinitionsPolicy Background
    • Include clinical indication, dosing regimen, and treatment setting.
    • Attach supporting medical records and any required specialty documentation for + products.
    Denial Risk

    Precertification Failure May Result in Denial

    Failure to obtain required precertification may result in claim denial or member financial liability when drugs from the Provider‑Administered Precertification Drug List are administered in a provider office, outpatient facility, or home health setting. Providers are responsible for verifying PA approval prior to administration.

    • Claims for non‑precertified administrations of listed drugs may be denied.
    • Providers may be financially responsible for services rendered without prior authorization.
    Note

    Reference — Full List and Policy Details

    See the online Provider‑Administered Drug Policies for the complete, monthly‑updated list of affected products and any product‑specific precertification instructions or exceptions.

    • Online policies: MN-Policies.Exploremyplan.com (select 'Provider‑Administered Drug Policies')